Firm News
Wiggin and Dana Advises Veradermics in Series B Financing
Wiggin and Dana recently represented Veradermics, Incorporated, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company, in its $75 million Series B financing. The financing was led by Suvretta Capital Management and included new investors Longitude Capital, Surveyor Capital (a Citadel company), Osage University Partners, and PhiFund. Existing investors, including JW Childs Associates, Connecticut Innovations, and Vlad Coric, MD, also participated in the round.
The company intends to use the financing to fund the ongoing pivotal clinical development of Veradermicsโ lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL).
The Wiggin deal team consisted of Evan Kipperman, Elishama Rudolph and Celena Dyal.
To learn more and read the official press release, please click here.
